Skip to main content

Table 2 Baseline characteristics of the study sample

From: 3D vena contracta area after MitraClip© procedure: precise quantification of residual mitral regurgitation and identification of prognostic information

Age [years] 77.0 ± 5.8
Female 41.4 (12/29)
Heart rate [bpm] 74 ± 9
Systolic blood pressure [mmHg] 119 ± 19
Diastolic blood pressure [mmHg] 67 ± 14
Body mass index [kg/m2] 25.8 ± 4.2
NT-proBNP [pg/ml] median(P25;75) 3618 (1619; 5782)
Serum creatinine [mg/dl] median(P25;75) 1.1 (1.0; 1.6)
logEuroScore [%] median(P25;75) 18.5 (12.7; 32.2)
NYHA functional class
 I 0 (0/29)
 II 24.1 (7/29)
 III 62.1 (18/29)
 IV 13.8 (4/29)
Comorbidities
 DCM 10.3 (3/29)
 Coronary artery disease 62.1 (18/29)
 Diabetes mellitus II 34.5 (10/29)
Medical/Device treatment
 High-ceiling diuretics 100 (29/29)
 ACE inhibitors 48.3 (14/29)
 MRA 62.1 (18/29)
 Beta-blocker 89.7 (26/29)
 CRT 6.9 (2/29)
  1. Shown are percentage of subjects (number of subjects / total number of subjects in parentheses) or mean ± standard deviation, if not indicated otherwise
  2. NYHA New York Heart Association, DCM dilated cardiomyopathy, ACE angiotensin- converting enzyme, MRA mineralocorticoid receptor antagonist, CRT cardiac resynchronization therapy